乳癌液态切片市场规模、份额、成长分析（按循环生物标记、应用、地区）- 产业预测，2024-2031 年

2022年全球液态切片市场规模为10.1亿美元，从2023年的12.4亿美元成长到2031年的63.7亿美元，预计在预测期间（2024-2031年）将以复合年增长率成长。 %。

在人们对非侵入性诊断方法的认识和采用不断提高的推动下，全球液态切片市场正在显着增长。这项创新技术有助于检测肿瘤特异性基因突变、循环性肿瘤细胞和游离 DNA，这对于早期诊断、治疗方法选择和监测治疗反应至关重要。随着正在进行的研究和开发提高液态切片测试的灵敏度和特异性，预计市场将会扩大。生物技术公司和医疗机构之间的合作，加上对个人化和针对性乳癌治疗的需求不断增长，正在进一步推动市场扩张。总体而言，技术创新和临床应用的结合可能会推动液态切片市场在未来几年显着成长。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 案例研究分析

液态切片市场规模：按循环生物标记和复合年增长率（2024-2031）

• 市场概况
• 循环性肿瘤细胞（CTCS）
• 循环游离 DNA (CFDNA)
• 细胞外囊泡（EVS）
• 其他循环生物标记

液态切片市场规模：按应用和复合年增长率（2024-2031）

• 市场概况
• 早期发现/筛检
• 诊断
• 治疗选择
• 监视

液态切片市场规模：按最终用户和复合年增长率（2024-2031）

• 市场概况
• 医院
• 诊所
• 其他的

液态切片市场规模及复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• F. Hoffmann-La Roche Ltd
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Guardant Health Inc.
• QIAGEN
• Biocept Inc.
• Thermo Fisher Scientific
• Adaptive Biotechnologies
• Myriad Genetics
• Fluxion Biosciences Inc.
• Biodesix
• Exosome Diagnostics Inc.
• Epic Sciences
• PapGene
• Pathway Genomics（OME Care）
• Agena Bioscience
• MDxHealth
• Janssen Diagnostics
• Abbott

结论和建议

Global Breast Cancer Liquid Biopsy Market size was valued at USD 1.01 billion in 2022 and is poised to grow from USD 1.24 billion in 2023 to USD 6.37 billion by 2031, growing at a CAGR of 22.7% during the forecast period (2024-2031).

The global breast cancer liquid biopsy market is witnessing substantial growth, spurred by rising awareness and the adoption of non-invasive diagnostic methods. This innovative technology facilitates the detection of tumor-specific genetic mutations, circulating tumor cells, and cell-free DNA, critical for early diagnosis, treatment selection, and monitoring responses to therapies. As ongoing research and development improve the sensitivity and specificity of liquid biopsy tests, market expansion is anticipated. Collaborative efforts between biotech firms and healthcare institutions, coupled with increasing demand for personalized and targeted breast cancer therapies, are further propelling the market's progression. Overall, the convergence of innovation and clinical application positions the liquid biopsy market for notable growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Breast Cancer Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Breast Cancer Liquid Biopsy Market Segmental Analysis

Global Breast Cancer Liquid Biopsy Market is segmented by circulating biomarkers, application, end users and region. Based on circulating biomarkers, the market is segmented into circulating tumor cells (CTCS), circulating cell-free DNA (CFDNA), extracellular vesicles (EVS) and other circulating biomarkers. Based on application, the market is segmented into early detection/screening, diagnosis, treatment selection and monitoring. Based on end users, the market is segmented into hospitals, clinics and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market is primarily propelled by the growing demand to effectively tackle breast cancer. The rising use of liquid biopsy methods serves as a key motivator, as these techniques facilitate the analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and various biomarkers found in blood samples. This innovation enables healthcare providers to make better-informed treatment choices. Furthermore, liquid biopsies can detect resistance mutations and minimal residual disease, enhancing personalized treatment approaches. As a result, this technology not only improves patient outcomes but also contributes to lowering overall healthcare expenses.

Restraints in the Global Breast Cancer Liquid Biopsy Market

The global breast cancer liquid biopsy market faces several significant restraints, primarily stemming from inadequate investment in healthcare infrastructure. While liquid biopsy tests show considerable promise, their high costs present a substantial barrier to accessibility, particularly for patients with limited financial means or those in areas with poor healthcare funding. The considerable investment required for the development and deployment of advanced liquid biopsy technologies often leads to elevated testing costs, making them less feasible for many individuals. Furthermore, challenges related to reimbursement policies and regulatory approvals hamper widespread adoption, highlighting the critical need to address these financial barriers to enhance equitable access to these crucial diagnostic tools for breast cancer patients worldwide.

Market Trends of the Global Breast Cancer Liquid Biopsy Market

The Global Breast Cancer Liquid Biopsy market is witnessing a significant upward trend, driven by the increasing demand for non-invasive diagnostic methods aimed at early detection and monitoring of breast cancer. As healthcare professionals and patients alike seek alternatives to traditional tissue biopsies, liquid biopsies are gaining traction for their ability to provide timely and accurate genomic insights with minimal discomfort. Technological advancements in assay development and an escalating focus on personalized medicine are further propelling this market. Additionally, rising awareness and supportive regulatory frameworks are fostering a conducive environment for innovation, ultimately driving growth in the breast cancer liquid biopsy sector.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Case Study Analysis

Global Breast Cancer Liquid Biopsy Market Size by Circulating Biomarkers & CAGR (2024-2031)

• Market Overview
• Circulating Tumor Cells (CTCS)
• Circulating Cell-Free DNA (CFDNA)
• Extracellular Vesicles (EVS)
• Other Circulating Biomarkers

Global Breast Cancer Liquid Biopsy Market Size by Application & CAGR (2024-2031)

• Market Overview
• Early Detection/Screening
• Diagnosis
• Treatment Selection
• Monitoring

Global Breast Cancer Liquid Biopsy Market Size by End Users & CAGR (2024-2031)

• Market Overview
• Hospitals
• Clinics
• Others

Global Breast Cancer Liquid Biopsy Market Size & CAGR (2024-2031)

• North America (Circulating Biomarkers, Application, End Users)
  • USA
  • Canada
• Europe (Circulating Biomarkers, Application, End Users)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Circulating Biomarkers, Application, End Users)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Circulating Biomarkers, Application, End Users)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Circulating Biomarkers, Application, End Users)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocept Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adaptive Biotechnologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fluxion Biosciences Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biodesix
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exosome Diagnostics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epic Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PapGene
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pathway Genomics (OME Care)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agena Bioscience
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Diagnostics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations